Rocket Pharma FY2024 net loss $258.7M ($2.73/sh); cash $372.3M; RP-A501 Phase 2 ongoing

ROCKET PHARMACEUTICALS, INC.

2024-FY EPS reported -$2.73

Net loss $258.7M ($2.73/sh) for FY2024 vs $245.6M ($2.92/sh) in FY2023.
Cash, equivalents and investments $372.3M at Dec 31, 2024; runway into Q3 2026.
Raised $182.5M net via Dec 2024 offering of 15.2M shares at $12.50/sh.
RP-A501 Phase 2 pivotal dosing ongoing; NEJM publication shows efficacy up to 5 years.
RP-A601 low dose cohort fully enrolled; initial data expected H1 2025. BAG3-DCM IND on track H1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.